Previously, by studying these proteins, we identified that targeting these proteins in different ways might have different responses in cancer cells, including cell cycle arrest or apoptosis. See: https://t.co/aY8lyTZZq1
Here are @DocWang4 works from our lab as major contributor. Congratulations, and cannot wait to see you achieve more as a wonderful neurosurgeon as well as an amazing scientist. https://t.co/UDgC8TbdJN https://t.co/itP9qJtuuv https://t.co/IwOtSbGfRB
RT @TaliLev123: Adam Durbin speaks at #AACRepigen22 about his recently published @CD_AACR paper: EP300 Selectively Controls the Enhancer La…
RT @TaliLev123: Adam Durbin speaks at #AACRepigen22 about his recently published @CD_AACR paper: EP300 Selectively Controls the Enhancer La…
Adam Durbin speaks at #AACRepigen22 about his recently published @CD_AACR paper: EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma https://t.co/lllRk6y5Qu https://t.co/Y93M7EAgkv
RT @DrBaileeSliker: Want more on PROTACs today after the #AACR22 Targeted Protein Degradation session? Read the related research article an…
Elegant study by @DanaFarber @StJude - identified EP300 as therapeutic target for rare pediatric CNS #cancer (neuroblastoma) - developed EP300 PROTAC degrader #genetics https://t.co/NMcZ9llFDB
RT @ElizSMcKenna: At the #AACR22 session on Advances in #Neuroblastoma Research? ICYMI in @CD_AACR: EP300 Selectively Controls the Enhancer…
RT @JunQiLab: We are also recruiting. Come talk to me at my poster if you are interested in joining or collaborating.
We are also recruiting. Come talk to me at my poster if you are interested in joining or collaborating.
RT @ElizSMcKenna: At the #AACR22 session on Advances in #Neuroblastoma Research? ICYMI in @CD_AACR: EP300 Selectively Controls the Enhancer…
RT @ElizSMcKenna: At the #AACR22 session on Advances in #Neuroblastoma Research? ICYMI in @CD_AACR: EP300 Selectively Controls the Enhancer…
Thank you @ElizSMcKenna for promoting our science. i would love to swing by AACR publication booth to say hi.
At the #AACR22 session on Advances in #Neuroblastoma Research? ICYMI in @CD_AACR: EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma @ADurbinLab @DocWang4 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber https://t.co/kB
RT @DrBaileeSliker: Want more on PROTACs today after the #AACR22 Targeted Protein Degradation session? Read the related research article an…
RT @DrBaileeSliker: Want more on PROTACs today after the #AACR22 Targeted Protein Degradation session? Read the related research article an…
Want more on PROTACs today after the #AACR22 Targeted Protein Degradation session? Read the related research article and news story published in @CD_AACR https://t.co/Fmhl4O5Ayb https://t.co/kxvkHoTfOW
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
RT @JunQiLab: EP300 interacts with CRC members in neuroblastoma through protein-protein interaction, which is not interrupted by inhibition…
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
This will be part of my discussion in my poster for the annual AACR meeting @AACR. Swing by my poster on Wednesday, love to chat.
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
RT @CD_AACR: To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplifi…
RT @JunQiLab: EP300 interacts with CRC members in neuroblastoma through protein-protein interaction, which is not interrupted by inhibition…
EP300 interacts with CRC members in neuroblastoma through protein-protein interaction, which is not interrupted by inhibition but can be destroyed by selective degradation.
To learn more about cancer epigenetics, check out the paper, EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. https://t.co/Q3gdSNu6G2 @ADurbinLab @DocWang4 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber #AACR22 #e
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
RT @JunQiLab: We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegm…
We are excited to see our story in the final format. Thank you so much @CD_AACR, and the wonderful team, @ADurbinLab @KStegmaier_DFCI, Dr. Tom Look work on this exciting project with us for three years. Thanks again to @AlexsLemonade for the support.
RT @CD_AACR: From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocW…
From the March issue: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma by @ADurbinLab, @DocWang4 et al. https://t.co/9mDArOctK2 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber #epigenetics #PROTAC https://t.co/EGqpN
RRIDs were included in the Cancer Discovery paper "EP300 Selectively Controls the Enhancer Landscape…" (https://t.co/Izci7qWFEg). Thank you for making your #methodsmatter. #RRID
RT @isciverse: Just Published | Cancer Discovery #EP300 Selectively Controls the #Enhancer Landscape of MYCN-Amplified #Neuroblastoma. @C…
RT @ADurbinLab: So happy to see this out in final form! @JunQiLab @KStegmaier_DFCI @StJudeResearch @DFBC_PedCare
RT @ADurbinLab: So happy to see this out in final form! @JunQiLab @KStegmaier_DFCI @StJudeResearch @DFBC_PedCare
RT @isciverse: Just Published | Cancer Discovery #EP300 Selectively Controls the #Enhancer Landscape of MYCN-Amplified #Neuroblastoma. @C…
RT @isciverse: Just Published | Cancer Discovery #EP300 Selectively Controls the #Enhancer Landscape of MYCN-Amplified #Neuroblastoma. @C…
RT @ADurbinLab: So happy to see this out in final form! @JunQiLab @KStegmaier_DFCI @StJudeResearch @DFBC_PedCare
RT @ADurbinLab: So happy to see this out in final form! @JunQiLab @KStegmaier_DFCI @StJudeResearch @DFBC_PedCare
thanks to the team @CD_AACR allow us to make suggestions on the graphic design. I really like the color and the idea.
So happy to see this out in final form! @JunQiLab @KStegmaier_DFCI @StJudeResearch @DFBC_PedCare
Just Published | Cancer Discovery #EP300 Selectively Controls the #Enhancer Landscape of MYCN-Amplified #Neuroblastoma. @CD_AACR @ElizSMcKenna Congratulations 💐💐💐 @ADurbinLab @DocWang4 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber https://t.c
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYu…
RT @JunQiLab: We are excited that people already start requesting our chemical probes. Cannot wait to learn more about the difference betw…
We are excited that people already start requesting our chemical probes. Cannot wait to learn more about the difference between EP300 and CBP together with our collaborators @ADurbinLab @KStegmaier_DFCI and with cancer research community.
EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma. #epigenetics #PROTAC. https://t.co/CewevYuXgH @ADurbinLab @DocWang4 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber https://t.co/6AHXYeHOWA
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @JunQiLab: we are excited to have our science as well as our chemical probe published.
we are excited to have our science as well as our chemical probe published.
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
Interesting: “We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depend on EP300, whereas CBP has a limited role.”
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
RT @ElizSMcKenna: Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @D…
Now online in @CD_AACR: EP300 selectively controls the enhancer landscape of MYCN-amplified #neuroblastoma @ADurbinLab @DocWang4 @KStegmaier_DFCI @JunQiLab @StJudeResearch @DanaFarber #epigenetics #PROTAC https://t.co/d6LTPCrneX
RT @NatRevClinOncol: The majority of high-risk paediatric neuroblastoma cell lines require histone acetyltransferase EP300, whereas its par…
RT @NatRevClinOncol: The majority of high-risk paediatric neuroblastoma cell lines require histone acetyltransferase EP300, whereas its par…
The majority of high-risk paediatric neuroblastoma cell lines require histone acetyltransferase EP300, whereas its paralogue CBP seems dispensable; the EP300-targeted PROTAC JQAD1 suppressed cell growth in vitro and tumour growth in mice: https://t.co/j1Q6
RT @StJudeResearch: Scientists at St. Jude and @DanaFarber have created a compound to selectively target EP300 in neuroblastoma. Read the @…
RT @JunQiLab: our manuscript is now online. Congratulations to all the team members!!! @ADurbinLab @DocWang4 @KStegmaier_DFCI . We really…
RT @JunQiLab: We really appreciate @AACR journals that accepted and published our KDM5 story @BCD_AACR @_TanyaBondar_ and EP300 story @CD_…
RT @ADurbinLab: Targeting EP300 selectively...a tweetorial! 1/x Live now @CD_AACR, our most recent manuscript detailing our new strategy fo…
RT @StJudeResearch: Scientists at St. Jude and @DanaFarber have created a compound to selectively target EP300 in neuroblastoma. Read the @…
Untangling the effects of CBP vs p300 has been super challenging - and these chemical tools will be key to doing so! Amazing findings in neuroblastoma, and likely more applications in the future. Congrats to Jun, Adam and all the scientists that worked on
RT @JunQiLab: our manuscript is now online. Congratulations to all the team members!!! @ADurbinLab @DocWang4 @KStegmaier_DFCI . We really…
RT @MilkaKostic: EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma - this discovery was made possible by JQ…
RT @vkwimalasena: pretty proud of this one from my work as a tech :’)
EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma - this discovery was made possible by JQAD1, a PROTAC based degrader for selectivity for EP300 over CBP. Wonderful use of degraders as research tools! https://t.co/uEPiAehlh3